Rahul Koul
Uttar Pradesh poised to become India’s premier healthcare and medical device hub: Dr. G.N. Singh
By Rahul Koul - May 08, 2026
Former DCGI and now advisor to UP CM highlights medical device growth, healthcare expansion, and investment opportunities in the state
Sun Pharma eyes biosimilars-led growth, Organon deal to build $12.4 billion global platform
By Rahul Koul - April 28, 2026
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
CDSCO rolls out prior intimation system to fast-track drug testing and R&D
By Rahul Koul - April 21, 2026
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
Pharma stocks face Q4 reality check amid global headwinds
By Rahul Koul - April 20, 2026
Analysts expect modest revenue growth but pressure on profitability in the March quarter
India must build its own agile biopharma innovation model: ICMR DG Dr Rajiv Bahl
By Rahul Koul - April 14, 2026
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
CDSCO reforms cut trial approval timelines by over 50%: DCGI Dr Rajeev Raghuvanshi
By Rahul Koul - April 14, 2026
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Gennova CEO Dr Sanjay Singh sees strong innovation momentum for India’s biopharma sector
By Rahul Koul - April 14, 2026
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Exclusive | Bharat Biotech’s ROTAVAC halves severe diarrhoea hospitalisations in children, landmark Nature study confirms
By Rahul Koul - April 10, 2026
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
India’s Dapagliflozin Moment: Why USFDA’s generic greenlight wave matters
By Rahul Koul - April 09, 2026
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
The Semaglutide Surge: How a diabetes therapy sparked India’s weight loss wave
By Rahul Koul - April 07, 2026
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
India’s bioeconomy hits $165.7 billion as govt unveils fresh biopharma push
By Rahul Koul - April 03, 2026
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
Indian pharma sector poised for a global leap beyond generics: K. Raja Bhanu, DG, PHARMEXCIL
By Rahul Koul - November 17, 2025
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Industry leaders call for a new era of collaboration, innovation, and self-reliance
By Rahul Koul - November 03, 2025
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Fostering closer ties between industry & academia imperative for sustainable growth
By Rahul Koul - July 25, 2024
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Pharma industry warming up towards adoption of digital technologies
By Rahul Koul - June 27, 2022
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
